Research Database PMU-SQQUID

PMU-Authors

Abstract

Multiple sclerosis (MS) is the most common chronic neurological disease in young adults in the western world. There was no specific treatment available for this serious disorder until the introduction of the immunomodulatory drug interferon-β in the mid-1990s. Since then, the number of agents and treatment strategies for MS has increased rapidly. Deeper knowledge on the heterogeneous nature of MS cleared the way for several more specific, more effective and more comfortable therapies. Here, because of the exciting recent developments concerning oral treatment forms for MS, we summarize the current state of approved and future therapy options. In particular, we highlight oral treatment options in MS.

Useful keywords (using NLM MeSH Indexing)

Administration, Oral

Animals

Drug Approval

Drug Design

Forecasting

Humans

Multiple Sclerosis/drug therapy

Multiple Sclerosis/therapy*